

A microscopic image showing a network of blue, fibrous structures, likely representing a cell or tissue structure. In the foreground, there are several bright red, spherical particles, which are nanocarriers. The background is dark, and there are some green, textured areas on the right side.

Mass Transport of Nanocarriers

edited by
Rita Elena Serda



Mass Transport of Nanocarriers

edited by
Rita Elena Serda

PAN STANFORD  PUBLISHING

Published by

Pan Stanford Publishing Pte. Ltd.
Penthouse Level, Suntec Tower 3
8 Temasek Boulevard
Singapore 038988

Email: editorial@panstanford.com

Web: www.panstanford.com

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Mass Transport of Nanocarriers

Copyright © 2013 by Pan Stanford Publishing Pte. Ltd.

All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the publisher.

For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy is not required from the publisher.

ISBN 978-981-4364-41-6 (Hardcover)

ISBN 978-981-4364-42-3 (eBook)

Printed in the USA

Contents

<i>Preface</i>	xvii
Part 1 Overview	1
1. Mass Transport: Barriers and Opportunities for Drug Delivery	3
<i>Rita E. Serda</i>	
1.1 Introduction	4
1.2 Macro Barriers: Journey to the Tumor	4
1.2.1 Endothelial Barriers	4
1.2.2 Epithelial Barriers	7
1.2.3 Mucosal Barriers	10
1.2.4 Cell-Based Transport Across Barriers	10
1.3 The Tumor Microenvironment	12
1.3.1 Vasculature	12
1.3.2 Lymphatic Drainage	13
1.3.3 Viscoelasticity	14
1.4 Cellular Barriers	15
1.4.1 Endocytosis	15
1.4.2 Intracellular Trafficking of Nanoparticles	16
1.4.3 Cellular Targeting	17
1.4.4 Tools for Cellular Imaging	17
1.5 Novel Design Approaches	19
1.6 Summary	20
Part 2 Macro Barriers: Journey to the Tumor	25
2. Biological Barriers: Targeting and Crossing the Endothelium	27
<i>Silvia Ferrati, Brenda Melendez, and Aaron Mack</i>	
2.1 Introduction	27
2.2 Biological Barriers to Transport	28
2.2.1 Barriers at the Systems Level	28

2.2.1.1	Mucus and epithelial barriers	28
2.2.1.2	Blood circulation and RES	36
2.2.1.3	Endothelial barrier	40
2.3	Organ and Tissue Level	42
2.4	Cellular Level	44
2.5	The Multistage System	46
2.6	Angiogenesis	47
2.6.1	VEGF	48
2.6.2	PLGF	49
2.6.3	Angiopoietin	50
2.7	Tumor Microenvironment	50
2.8	Tumor Vasculature	51
2.9	Therapies Targeting the Tumor Vasculature	53
2.9.1	Vascular-Disrupting Agents	54
2.9.2	Angiogenesis Inhibitors	55
2.10	Targeting Strategies	56
2.10.1	Peptides	56
2.10.1.1	Peptide synthesis	59
2.10.2	Viral Vectors	61
2.10.3	Phage Display Libraries	62
2.10.4	RGD Peptides	63
2.10.5	Aptamers	64
2.10.5.1	Thioaptamers	65
2.10.5.2	Aptamers for targeting	67
2.10.6	Antibodies	67
2.10.7	Antibody Mimetics	68
3.	Stromal Barriers to Delivery	83
	<i>Rosa F. Hwang</i>	
3.1	Tumor-Associated Stroma	83
3.2	Stroma Contributes to the Malignant Phenotype	84
3.2.1	Stroma Promotes Tumor Progression	84
3.2.2	Stroma Contributes to Resistance to Therapy	87
3.3	Stromal Barriers to Delivery: Possible Mechanisms	89
3.3.1	Stroma as a Physical Barrier	89
3.3.2	Tumor Vasculature Is Disorganized	90
3.3.3	Hypoxia	90

3.3.4 Stroma-Derived Factors	91
3.4 Conclusions	91
4. Mucosal Barriers to Drug- and Gene-Loaded Nanoparticles	97
<i>Myung Soo Kim, Ying-Ying Wang, and Samuel K. Lai</i>	
4.1 Introduction	97
4.2 Need for Engineering Nanoparticles That Overcome the Mucus Barrier	98
4.2.1 Fate of Conventional, Mucoadhesive Nanoparticles	99
4.2.1.1 Sustained and targeted drug delivery using mucus-penetrating particles	101
4.3 Composition of Mucus	103
4.3.1 Mucins	103
4.3.2 DNA	106
4.3.3 Lipids	106
4.3.4 Salts	106
4.3.5 Proteins	107
4.3.6 Cells and Cellular Debris	107
4.4 Properties of the Mucus Barrier	108
4.4.1 Luminal vs. Adherent Mucus Layers	108
4.4.2 Thickness of Mucus Layers and Turnover Rate	109
4.5 Diffusional Barrier Properties of Mucus	111
4.5.1 Understanding Particle Diffusion in Mucus: Macrorheology vs. Microrheology	112
4.5.2 Microstructure of Mucus	113
4.5.3 Adhesive Trapping of Particles	114
4.6 Engineering Mucus-Penetrating Particles	117
4.6.1 Understanding Physiochemical Properties Necessary for MPP	117
4.6.2 Learning from Viruses	118
4.6.3 PEGylation	118
4.6.4 Size	122
4.6.5 Other Methods to Improve Mucosal Delivery	122

Part 3 The Tumor Microenvironment	137
5. Modeling the Tumor Microenvironment as a Biobarrier in Cancer Nanotherapeutics	139
<i>Hermann B. Frieboes, Kenji Yokoi, Bhuvanesh Dave, Fazle Hussain, and Biana Godin</i>	
5.1 Introduction	140
5.1.1 Multi-Scale Biobarriers	140
5.1.2 Effect of Tumor Microenvironment on Therapeutic Outcome	141
5.2 Modeling the Tumor Microenvironment	143
5.2.1 Effect of Tumor Microenvironment on Cancer Cell Survival	143
5.2.2 <i>In silico</i> Modeling of the Tumor Microenvironment	145
5.2.3 Discrete, Continuum, and Hybrid Models of the Tumor Microenvironment	146
5.2.4 Modeling of Therapy to Overcome Sub-Optimal Delivery of Agents in the Tumor Microenvironment	146
5.2.5 Cancer Nanotherapeutics: Design Considerations	148
5.3 Nanovectors and Tumor Biobarriers	150
5.3.1 Physiology of Tumor Vasculature	150
5.3.2 Passive Accumulation vs. Molecular Targeting in Delivery of Nanotherapeutics: <i>A Posse Ad Esse</i>	153
5.3.3 Gradients in Tumor Tissue	155
5.3.4 Effect of Angiogenic Blood Vessels on Transport of Nanotherapeutics	155
5.3.4.1 Vascular topology	155
5.3.4.2 Hemodynamics	156
5.3.4.3 Vascular diffusivity	157
5.3.5 Drug Release from a Nanovector	158
5.4 Modeling Tumor Growth and Shrinkage in Response to Therapy	159
5.4.1 Modeling Tumor Growth	159
5.4.2 Modeling Therapeutic Response	160
5.4.2.1 Pharmacokinetic parameters	160
5.4.2.2 Pharmacodynamic parameters	162

5.5	Computational Simulations of Therapeutic Response	163
5.5.1	Description of Simulations	163
5.5.1.1	General considerations in simulating therapeutic response	163
5.5.1.2	Simulation of DNA-bound drug distribution	165
5.5.2	Effect of Heterogeneity in Drug and Cell Nutrients	167
5.5.3	Simulating the Tumor Response to Therapeutic Nanovectors	171
5.6	Conclusions and Future Considerations	172
6.	Tumor Microenvironment	185
	<i>Christopher H. Loo</i>	
6.1	Introduction	185
6.2	Vasculature	186
6.2.1	Vascular Endothelial Growth Factor	187
6.2.2	VEGF and Associated Receptors	187
6.2.3	Vessel Permeability	188
6.2.4	Endothelial Cell Activation	189
6.2.5	Proliferation	190
6.2.6	Invasion and Migration	190
6.2.7	Survival	190
6.2.8	Recruitment of Endothelial Cell Progenitors	191
6.2.9	Vasculogenic Mimicry, Oncogene Addiction, and the Angiogenic Switch	191
6.2.9.1	Vasculogenic mimicry	191
6.2.9.2	Oncogene addiction	192
6.2.9.3	Angiogenic switch	192
6.2.10	Clinical Applicability	193
6.2.11	Multiple Molecular Targets Required	194
6.3	Hypoxia	195
6.3.1	Biochemistry of Hypoxia-Inducible Factor	195
6.3.2	HIF Activation	196
6.3.3	Biochemistry of HIF Activation	197
6.3.4	Tumor Angiogenesis	198

6.3.5	Cell Survival and/or Death	198
6.3.6	Metabolism	200
6.3.7	Regulation of pH	201
6.3.8	Metastasis	202
6.3.9	Hypoxia, Oncogenes, and Tumor Suppressor Genes	202
6.3.10	Hypoxia, HIF, and Therapeutics	203
6.4	Pericytes	203
6.4.1	Pericyte Involvement in Tumor Angiogenesis and Metastasis	204
6.4.2	Pericyte-Mediated Vessel Destabilization	204
6.4.3	Endothelial Cell Growth	204
6.4.4	Ang2/Tie Signaling	206
6.4.5	Targeting Stromal Cells as Molecular Targets in Models Against Cancer (Pancreatic, Colon, and Lung)	208
6.4.5.1	Pancreatic cancer	208
6.4.5.2	Colon cancer	209
6.4.5.3	Lung cancer	210
6.5	Conclusions	210

Part 4 Cellular Barriers 221

**7. Imaging Tools for Cellular Uptake and
Intracellular Trafficking 223**

Jared Burks

7.1	Objectives	224
7.2	Illumination	228
7.3	Detectors (CCD Cameras and Photomultiplier Tube)	229
7.4	Filters	230
7.5	Automated Stages	230
7.6	The Microscope	231
7.7	Live Cell Imaging	232
7.7.1	Phototoxicity and Photostability	234
7.8	Fluorescent Probes	235
7.9	Fluorescent Proteins	235
7.10	Quantum Dots	236
7.11	Dyes	237

9.2.4	Alternate Location for Escape	276
9.3	Cytoplasmic Transport and Organelle Targeting	276
9.3.1	Diffusive Transport	277
9.3.2	Active Transport	278
9.3.3	Nuclear Targeting	279
9.3.4	Targeting Other Organelles	279
9.4	Cargo Release	280
9.4.1	Reducible Polymers	282
9.4.2	pH-Sensitive Polymers	283
9.4.3	Photosensitive Polymers	284
9.5	Cytoplasmic Instability	285
9.5.1	Nucleases	285
9.5.2	Cellular Expulsion	285
9.5.3	Nanoparticle Aggregation	287
9.6	Integrated Mathematical Models of Cellular Barriers	287
9.6.1	Macroscopic Modeling	288
9.6.2	Microscopic Modeling	289
9.7	Viruses: How Nature Overcomes Cellular Barriers	291
9.8	Conclusion	292
10.	Nanovectors Targeting Cell Surface Receptors	299
	<i>Srimeenakshi Srinivasan, Wouter H. P. Driessen, Bettina Proneth, Jenolyn F. Alexander, Renata Pasqualini, Wadih Arap, and Biana Godin</i>	
10.1	Introduction	299
10.1.1	The Cell Membrane as a Biological Barrier	299
10.1.2	Types of Cell Surface Receptors and Their Role in Intracellular Uptake	301
10.2	Cell Surface Biomarker Discovery	302
10.2.1	Ligand-Receptor Binding Strategies	303
10.2.1.1	<i>In vivo</i> phage display	303
10.2.1.2	Antibodies	306
10.2.1.3	Oligonucleotide-based combinatorial libraries	307
10.2.1.4	Considerations for ligand selection	307
10.2.2	Sequencing	309

10.2.3	Proteomics	310
10.3	Nanovectors-Modification Techniques for Targeting Cell Membrane Receptors	310
10.3.1	Aptamers	311
10.3.2	Proteins	313
10.3.3	Peptides	315
10.3.4	Other Ligands	315
10.4	Cell Membrane Targeted Nanocarriers for Advanced Diagnostics and Therapeutics	318
10.4.1	Cancer	319
10.4.2	Cardiovascular Diseases	326
10.4.3	Targeted Nanovectors in Endocrine and Metabolic Disorders	330
10.4.4	Neural Diseases	331
10.4.5	Infections and Inflammation	331
10.5	Effect of Carrier Geometry on Cell Surface Receptor Binding and Cellular Uptake	334
10.6	Conclusions	337
Part 5 Novel Design Approaches		361
11. The Fabrication and Mass Transport of Polymer Nanocarriers		363
<i>Litao Bai, Jason Sakamoto, and Haifa Shen</i>		
11.1	Introduction	363
11.2	Polymeric Nanoparticles as Nanocarriers	366
11.2.1	Preparation of Polymeric Nanoparticles	367
11.2.1.1	Preparation of polymer nanoparticles by solvent evaporation	367
11.2.1.2	Preparation of polymer nanoparticles by salting out	369
11.2.1.3	Preparation of polymer nanoparticles by solvent displacement/diffusion method	369
11.2.1.4	Preparation of polymer nanoparticles by supercritical fluid	370

11.2.1.5	Preparation of polymer nanoparticles by polymerization method	371
11.2.2	Drug Loading with Polymer Nanoparticles	371
11.2.3	Drug Release from Polymer Nanoparticles	372
11.3	Polymer-Drug Conjugates	372
11.3.1	HPMA Copolymer-Drug Conjugates	374
11.3.2	Polyglutamic Acid-Drug Conjugates	375
11.3.3	Dextran-Drug Conjugates	375
11.3.4	PEG-Drug Conjugates	376
11.4	Polymeric Micelles as Nanocarriers	377
11.4.1	Introduction	377
11.4.2	Preparation and Drug Loading of Polymeric Micelles	379
11.4.3	Drug Release from Polymeric Micelles	381
11.5	Dendrimer Nanocarriers	383
11.5.1	Introduction	383
11.5.2	Loading of Dendrimers by Physical Encapsulation	385
11.5.3	Loading of Dendrimers by Chemical Conjugation	387
11.5.4	Fabrication of Multifunctional Dendrimer Conjugations	388
11.6	Conclusion and Prospects	388
12.	Morphology Control of Nanotextured Drug Carriers	409
	<i>Ye Hu and Kevin Lin</i>	
12.1	Introduction	409
12.2	Porous Silicon Microparticles for Drug Delivery	412
12.2.1	Synthesis of Porous Silicon	412
12.2.2	Vascular Targeting and Margination	413
12.2.3	Biodistribution	416
12.3	Spherical Silica Particles for Drug Delivery	417
12.3.1	Methods for Particle Synthesis	418
12.3.1.1	Synthesis of M41S-based delivery particles	418

12.3.1.2	Synthesis of SBA-15-based delivery particles	419
12.3.1.3	Synthesis of porous hollow nanoparticles	420
12.3.2	Effect of Mesostructure on Drug Delivery	421
12.3.2.1	Effect of size	421
12.3.2.2	Surface area and pore volume/ geometry	422
12.3.2.3	Functionalization	422
12.3.3	Stimuli-Modulated Release	424
	<i>Index</i>	431